Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1983 2
1984 3
1985 3
1986 2
1987 3
1988 5
1989 1
1990 3
1991 4
1992 10
1993 7
1994 11
1995 13
1996 13
1997 14
1998 8
1999 15
2000 12
2001 8
2002 13
2003 17
2004 19
2005 16
2006 15
2007 25
2008 18
2009 19
2010 45
2011 48
2012 68
2013 80
2014 61
2015 56
2016 51
2017 62
2018 61
2019 50
2020 71
2021 49
2022 32
2023 27
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

929 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Lung Non-Small Cell Squamous Carcinoma"
Page 1
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6. Lancet Oncol. 2016. PMID: 27283860 Free PMC article. Clinical Trial.
BACKGROUND: BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown antitumour activity in patients with BRAF(V600E)-mutant NSCLC. ...Serious adv …
BACKGROUND: BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small …
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Hellmann MD, et al. Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5. Lancet Oncol. 2017. PMID: 27932067 Free PMC article. Clinical Trial.
BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. ...Eligible patients were aged 18 years or older with histologically or cytologically confirmed r …
BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC …
Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy.
Matsubara T, Hirai F, Yamaguchi M, Hamatake M. Matsubara T, et al. Anticancer Res. 2021 Oct;41(10):5157-5163. doi: 10.21873/anticanres.15333. Anticancer Res. 2021. PMID: 34593467
BACKGROUND/AIM: Adjuvant platinum-based chemotherapy (APC) has been the standard of care for patients with non-small-cell lung cancer (NSCLC) who have undergone complete pulmonary resection. ...On multivariate analyses, PNI was an independent predic …
BACKGROUND/AIM: Adjuvant platinum-based chemotherapy (APC) has been the standard of care for patients with non-small-cell …
Segmentectomy for clinically early-stage primary squamous cell carcinoma of the lung.
Kagimoto A, Tsutani Y, Shimada Y, Mimae T, Miyata Y, Ito H, Nakayama H, Ikeda N, Okada M. Kagimoto A, et al. Thorac Cancer. 2022 Dec;13(24):3477-3485. doi: 10.1111/1759-7714.14707. Epub 2022 Nov 8. Thorac Cancer. 2022. PMID: 36346136 Free PMC article.
BACKGROUND: Squamous cell carcinoma of the lung-the second most common subtype of lung cancer-has a poorer prognosis than lung adenocarcinoma. ...METHODS: Patients who underwent lobectomy or segmentectomy for clinically node-negati …
BACKGROUND: Squamous cell carcinoma of the lung-the second most common subtype of lung cancer-has a poore …
Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis.
He J, Li Y, An J, Hu L, Zhang J. He J, et al. World J Surg Oncol. 2017 Feb 2;15(1):36. doi: 10.1186/s12957-017-1105-8. World J Surg Oncol. 2017. PMID: 28148271 Free PMC article.
BACKGROUND: Previous studies have demonstrated survival benefits for local treatment in solitary metastatic non-small cell lung cancer (NSCLC).This study aimed to investigate the effect of local surgery for NSCLC with pulmonary oligometastasis. ...RESU …
BACKGROUND: Previous studies have demonstrated survival benefits for local treatment in solitary metastatic non-small cell …
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q. Wei XW, et al. Thorac Cancer. 2020 Jun;11(6):1512-1521. doi: 10.1111/1759-7714.13419. Epub 2020 Apr 14. Thorac Cancer. 2020. PMID: 32291971 Free PMC article.
BACKGROUND: Tyrosine kinase domain (TKD) mutation and particularly exon 20 insertion mutations of ERBB2 have been extensively reported in non-small cell lung cancer (NSCLC). Due to the increased accessibility of next-generation sequencing, more ERBB2 m …
BACKGROUND: Tyrosine kinase domain (TKD) mutation and particularly exon 20 insertion mutations of ERBB2 have been extensively reported in …
Hepatectomy for oligo-recurrence of non-small cell lung cancer in the liver.
Ishige F, Takayama W, Chiba S, Hoshino I, Arimitsu H, Yanagibashi H, Iwatate Y. Ishige F, et al. Int J Clin Oncol. 2018 Aug;23(4):647-651. doi: 10.1007/s10147-018-1262-y. Epub 2018 Mar 6. Int J Clin Oncol. 2018. PMID: 29511939
BACKGROUND: The prognosis of metastatic recurrent non-small cell lung cancer (NSCLC) is poor, and chemotherapy improves survival by only a few months. ...RESULTS: Primary tumor histopathological types included five cases of squamous …
BACKGROUND: The prognosis of metastatic recurrent non-small cell lung cancer (NSCLC) is poor, and …
Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes.
Kayawake H, Okumura N, Yamanashi K, Takahashi A, Itasaka S, Yoshioka H, Nakashima T, Matsuoka T. Kayawake H, et al. Gen Thorac Cardiovasc Surg. 2019 Sep;67(9):773-781. doi: 10.1007/s11748-019-01076-9. Epub 2019 Feb 6. Gen Thorac Cardiovasc Surg. 2019. PMID: 30725275
OBJECTIVES: When induction therapy followed by surgery for locally advanced non-small cell lung cancer results in pathological complete response, the prognosis is excellent; however, relapses can occur. We analyzed the predictive factors …
OBJECTIVES: When induction therapy followed by surgery for locally advanced non-small cell lung cancer results i …
Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
Xu T, Li D, He Y, Zhang F, Qiao M, Chen Y. Xu T, et al. World J Surg Oncol. 2018 Mar 20;16(1):60. doi: 10.1186/s12957-018-1362-1. World J Surg Oncol. 2018. PMID: 29558957 Free PMC article.
BACKGROUND: The anti-cancer role of metformin has been reported in many different kinds of solid tumors, but how it affects non-small cell lung cancer (NSCLC) is currently elusive. The aim of this study was to investigate the influence of metformin tre …
BACKGROUND: The anti-cancer role of metformin has been reported in many different kinds of solid tumors, but how it affects non-sm …
The progression of non-small cell lung cancer from diagnosis to surgery.
McPherson I, Bradley NA, Govindraj R, Kennedy ED, Kirk AJB, Asif M. McPherson I, et al. Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1882-1887. doi: 10.1016/j.ejso.2020.08.013. Epub 2020 Aug 15. Eur J Surg Oncol. 2020. PMID: 32847696
This study aims to quantify the T-stage progression and growth of non-small cell lung cancers (NSCLCs) between radiological diagnosis and resection, and its impact on disease recurrence and survival. ...Upstaging was independently associated wit …
This study aims to quantify the T-stage progression and growth of non-small cell lung cancers (NSCLCs) between r …
929 results